Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID03749538

Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies

Led by University of Sao Paulo · Updated on 2024-12-05

40

Participants Needed

1

Research Sites

30 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the safety and effectiveness of acute transcranial direct current stimulation in patients with systemic autoimmune myopathies, a group of diseases that mainly affect skeletal muscles. These diseases vary widely, and this study addresses the lack of previous research on using this stimulation technique in such patients. The study is designed as a prospective, randomized, double-blind, placebo-controlled trial to rigorously test this approach. Participants will be assigned randomly to one of two groups: one receiving transcranial direct current stimulation and the other receiving a placebo session. The stimulation involves placing two electrodes on the head, targeting the primary motor cortex, with a mild electric current delivered for 20 minutes while the patient is seated. This procedure will be repeated once daily for three days. The placebo group will not receive the actual stimulation. During the study, participants will be monitored closely for safety by checking for any treatment-related side effects shortly after stimulation and again after eight weeks. Researchers will also assess muscle disease activity, muscle strength, patient and physician evaluations, and blood muscle enzyme levels before, shortly after, and at 3 and 8 weeks post-stimulation. The study lasts for several weeks with multiple assessments to understand the treatment's impact and safety over time.

CONDITIONS

Brief Title

Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of systemic autoimmune myopathy based on EULAR/ACR 2017 criteria or Connors et al. criteria
  • Objective muscle limb weakness present
  • Age between 18 and 80 years
Not Eligible

You will not qualify if you...

  • Diagnosis of any neoplasia (cancer)
  • Use of a heart pacemaker
  • Presence of metallic clips inside the body
  • Active infections such as HIV, HTLV-1, or Hepatitis
  • Pregnancy
  • History of seizures or epilepsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 3 days

Participants receive either active transcranial direct current stimulation sessions or placebo sessions. Active stimulation involves three daily sessions of 20 minutes each.

3 daily visits (in-person) for stimulation sessions

Follow-up

Duration - 8 weeks

Participants are monitored for safety and efficacy outcomes up to 8 weeks after stimulation.

Assessments at 30 minutes, 3 weeks, and 8 weeks after last stimulation

Trial Site Locations

Total: 1 location

1

Samuel K Shinjo

São Paulo, Brazil, 01246903

Actively Recruiting

Loading map...

Research Team

S

Samuel K Shinjo

S

Sao Paulo University

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

Characterization of Familial Myopathy and Paget Disease of B...

Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here